Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics (NASDAQ: AKTX) reported Q1 2025 financial results and provided updates on its ADC development program. The company is developing novel Antibody Drug Conjugates with immuno-oncology payloads for cancer treatment, with its lead asset AKTX-101 targeting Trop2. The company appointed Mark Kubik as Head of Business Development - Oncology.
Financial highlights include a reduced net loss of $3.7 million compared to $5.6 million in Q1 2024. R&D expenses decreased to $0.8 million from $2.3 million, while G&A expenses dropped to $2.7 million from $3.7 million. The company held $2.6 million in cash as of March 31, 2025, with an additional $4.0 million received in April from a March 2025 offering that raised $6.0 million net.
Key upcoming milestones include presenting preclinical data for their PH1 payload ADC in H2 2025, exploring AKTX-101 in various solid tumors, and seeking strategic partnerships.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has released a corporate update video featuring their newly appointed President and Chief Executive Officer, Abizer Gaslightwala. The video, released on April 22, 2025, is available on the company's website under the Investors section's Presentations page at www.akaritx.com.
Akari Therapeutics (NASDAQ: AKTX) reported its 2024 financial results and corporate updates, marking a transformational year following its merger with Peak Bio Inc. The company is advancing next-generation precision bi-functional Antibody Drug Conjugates (ADCs) for cancer treatment.
Their lead program, AKTX-101, targets solid tumors with a novel spliceosome inhibitor payload, showing superior activity and better tolerability in preclinical models. The company reported a net loss of $21.6 million for 2024, compared to $16.8 million in 2023, with research and development expenses of $7.0 million.
With approximately $2.6 million cash as of December 2024, plus $6.6 million from a March 2025 private placement, Akari expects to fund operations into September 2025. The company appointed Abizer Gaslightwala as new CEO effective April 21, 2025, and is seeking licensing/strategic partners for AKTX-101.
Akari Therapeutics (NASDAQ: AKTX) has appointed Abizer Gaslightwala as President and CEO, effective April 21, 2025. Gaslightwala brings 25 years of biotechnology and pharmaceutical industry experience, most recently serving as SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, where he managed a $1B product portfolio.
The current President and CEO, Dr. Samir Patel, will remain on the Company's Board of Directors. During his 12-month tenure, Dr. Patel oversaw the successful merger of Peak Bio with Akari, transforming it into a targeted oncology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADCs) for cancer treatment.
Gaslightwala's extensive experience includes executive leadership roles at Amgen, Pfizer, and Johnson & Johnson, where he worked with major brands such as Kyprolis®, Vectibix®, and ELIQUIS®. He holds degrees from Cornell University and MIT, including an MBA from MIT Sloan School of Management.
Akari Therapeutics (Nasdaq: AKTX) has announced a private placement offering expected to raise $7.6 million in gross proceeds, with strong support from existing shareholders and board members. The financing includes the issuance of 6,637,626 unregistered American Depository Shares (ADSs) priced at $0.87 per ADS, along with Series A and B Warrants.
The deal structure includes the conversion of an existing $1 million convertible note by Board Chairman Dr. Huh, with expected cash proceeds of $6.6 million before fees. The warrants will have an exercise price of $0.87 per ADS, with Series A and B having terms of one and five years respectively.
Funds will be allocated towards the company's spliceosome inhibitor payload ADC technology platform, seeking license partners for its TROP-2 ADC program, and monetizing non-core assets. Paulson Investment Company serves as placement agent, with closing expected around March 5, 2025.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference.
During the event, CEO Dr. Samir Patel presented the top five reasons why investors and industry colleagues should focus on Akari in 2025. The presentation is now available for viewing online through the company's website and the conference platform.
Akari Therapeutics (NASDAQ: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has announced its participation in the Webull Corporate Connect Service (CCS) platform. This initiative aims to enhance shareholder communication and transparency by providing an additional channel for distributing corporate updates, including company news, earnings reports, product developments, and presentations.
Through the Webull CCS platform, AKTX will maintain direct communication with investors and release timely notifications about corporate developments. The company views this as a strategic addition to their existing corporate social channels and investor relations program, designed to build market awareness and increase visibility among investors.
Akari Therapeutics (NASDAQ: AKTX) has announced two key leadership appointments. Samir R. Patel, M.D., who has served as interim CEO since May 2024, has been appointed permanent Chief Executive Officer effective December 16, 2024. Additionally, Abizer Gaslightwala, a biotechnology industry veteran with over 25 years of experience, has joined the Board of Directors, while Michael Grissinger has resigned.
Dr. Patel highlighted the company's recent merger with Peak Bio and emphasized their focus on streamlining operations and executing their ADC platform strategy. Gaslightwala brings extensive experience from his current role as Senior Vice President and Franchise Head for Oncology at Jazz Pharmaceuticals, where he manages a $1B portfolio including products like ZIIHERA®, ZEPZELCA®, and RYLAZE®.
Akari Therapeutics (Nasdaq: AKTX) has appointed Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck, who previously served as Akari's CFO from 2019 to June 2023, brings over 20 years of biotechnology industry experience. During his previous tenure at Akari, he successfully raised over $50 million. Before rejoining Akari, he served as CFO at Aspira Women's Health. His extensive experience includes roles as Chief Commercial and Strategy Officer at Promethera Biosciences and Co-CEO at Cytonet. The appointment aims to strengthen the company's leadership team as it focuses on advancing its first-in-class ADC platform.